Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Uterine Cancer

Uterine Cancer Clinical Trial

Official title:

Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Patients With Uterine Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03583736
• Other study ID #: CASE3818
• Status: Withdrawn
• Phase: N/A
• Start date: June 27, 2018
• Est. completion date: June 1, 2020

Study information

• Verified date: June 2020
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project aims to evaluate whether rapid first contact with the oncologist the same day or the next day after pathologic diagnosis contributes to a decreased time to treatment, decreased patient anxiety and increased patient satisfaction.

Description:

Time to treatment (time from disease diagnosis to initiation of treatment) impacts outcomes in uterine cancer. When controlled for stage, patients with longer time to treatment tend to have less favorable outcomes. Similarly, longer time to treatment has a negative impact on patients' quality of life and markers for anxiety. Our experience at this institution suggests that the time to referral (time from uterine cancer diagnosis and the patients' first encounter with the oncologist) is variable and presents the greatest opportunity for decreasing time to treatment. Among the factors that contribute to the time to referral are the time taken by the referring provider to relay the diagnosis to the patient, time taken to schedule an appointment with the specialist, and the patient's availability to keep an appointment.

Virtual visits provide an opportunity to expedite consultation with the treating oncologist by removing some of the barriers that delay face-to-face visits. Among these barriers are patients' availability for a short notice face-to-face visit based on their work or family obligations, access to transportation, and mental preparedness.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 1, 2020
• Est. primary completion date: June 1, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Uterine cancer diagnosis on biopsy read by Cleveland Clinic Pathology Department

• Patients must be willing to participate in a virtual visit as the initial meeting with an oncologist at the Cleveland Clinic.

• Receive care at Fairview Hospital, Hillcrest Hospital or Cleveland Clinic Main Campus

• Internet connected smartphone or internet connected computer with webcam

• Participants must have email access

• English speaking

• Competent to make clinic decisions

Exclusion Criteria:

• No diagnosis of uterine cancer

Related Conditions & MeSH terms

• Uterine Cancer
• Uterine Neoplasms

Intervention

Behavioral:
• Virtual visit
Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
• Office visit
Scheduled office visit with oncologist following uterine cancer diagnosis.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Case Comprehensive Cancer Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to treatment following diagnosis to treatment initiation	How long between diagnosis to treatment	30 days
Secondary	Amount of anxiety demonstrated when virtual visits are added	Level of anxiety using GAD-7	30 days
Secondary	Number of patients willing to pay for a virtual visit	Assess patients valuation of virtual visits by measuring their willingness to pay	30 days
Secondary	Number of patients with improved satisfaction scores	Determine whether the addition of a rapid virtual visit improves patients satisfaction	30 days